Screener
Delcath Systems
DCTHDelcath Systems is an interventional oncology company specializing in the treatment of primary and metastatic liver cancers.
Earnings
Next report
Nov 3, 2026 (in a month)Revenue estimate$26.0M
EPS estimate-$0.10
Valuation & ratios
Segments
Competitors
By market cap
By revenue growth
Profile
Delcath Systems is an interventional oncology company specializing in the treatment of primary and metastatic liver cancers. The company's core value proposition is its proprietary drug/device combination system designed to deliver high-dose chemotherapy directly to the liver while minimizing systemic exposure. Its lead technology platform enables targeted treatment for patients with unresectable hepatic metastases, particularly those originating from uveal melanoma.
Competitive position
A specialized player in the liver-directed therapy market with FDA-approved orphan drug designations for its lead combination product.
GeographiesUnited States, Europe
Customer segmentsSpecialized Healthcare Providers, Tertiary Care Centers
Business modelProduct Manufacturing, Direct Sales
SuppliersPharmaceutical ingredient manufacturers, Medical device component suppliers, Contract manufacturers
CustomersOncology departments, Specialty hospitals, Medical distributors
CountryUnited States of America
Listed2000
Employees76.0
CEOGerard J. Michel
SectorHealthcare
IndustryMedical - Specialties
Websitedelcath.com
FilingsSEC EDGAR
FAQ
- What is Delcath Systems's market cap?
- Delcath Systems (DCTH) has a market capitalization of $534.7M and trades on NASDAQ.
- What is Delcath Systems's revenue and profitability?
- Delcath Systems generated $95.4M in trailing twelve-month revenue with net income of $5.1M, representing a net margin of 1.5%. Gross margin stands at 87.1%, with free cash flow of $17.5M. The latest reported period is Q2 2026.
- Who are Delcath Systems's competitors?
- Delcath Systems's key competitors include Boston Scientific, Merit Medical Systems, Citius Oncology, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Where is Delcath Systems headquartered?
- Delcath Systems is headquartered in United States of America and employs approximately 76 people. It has been publicly traded since 2000.
